Retatrutide (LY3437943) is an investigational triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors. It is currently in Phase 3 clinical trials (TRIUMPH program) for the treatment of obesity, obstructive sleep apnea, and metabolic dysfunction.

Is retatrutide FDA approved?

No, as of 2026, retatrutide has not yet been approved by the FDA or EMA. It is currently undergoing Phase 3 clinical trials focusing on safety and efficacy markers including weight-loss, liver fat reduction, and dysesthesia tracking.

What makes retatrutide different from tirzepatide or semaglutide?

Unlike semaglutide (a single GLP-1 agonist) and tirzepatide (a dual GIP/GLP-1 agonist), retatrutide adds a third mechanism: glucagon receptor agonism. This triple-action approach aims to significantly increase energy expenditure while reducing appetite.

Retatrutide Nda Submission Timeline Q4 2026 Q1 2027 Fda Review

Eli Lilly's investigational drug retatrutide is advancing toward a key milestone in the retatrutide nda submission timeline q4 2026 q1 2027 fda review process. The company plans to submit a New Drug Application (NDA) to the FDA in late 2026 or early 2027,[1] after completing the TRIUMPH Phase 3 trials showing up to 28.7% weight loss.[1] This timeline positions retatrutide for potential approval in 2027, offering hope for better obesity and type 2 diabetes treatments.

What Is Retatrutide? An Overview of Eli Lilly's Triple Agonist

Retatrutide, developed by Eli Lilly, is an experimental once-weekly injection for weight management. It targets obesity, type 2 diabetes (T2D), and related conditions with strong early results.

Unlike dual agonists like tirzepatide, retatrutide activates three hormones at once. This design aims for greater weight loss and metabolic benefits.

Mechanism of Action: GIP, GLP-1, and Glucagon Receptors

Retatrutide mimics three gut hormones: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon.

GIP and GLP-1 curb appetite and slow digestion, like drugs such as semaglutide.
Glucagon boosts energy use by breaking down fat and raising heart rate slightly.
Together, they led to 24.2%-28.7% weight loss in Phase 2 trials (NEJM).[2]

This triple action sets retatrutide apart in the retatrutide nda submission timeline q4 2026 q1 2027 fda review race.

Target Indications: Obesity, Type 2 Diabetes, CVD, and Knee Osteoarthritis

The drug targets adults with obesity or overweight plus comorbidities. Key areas include:

Obesity and overweight (primary focus).
Type 2 diabetes (T2D) for blood sugar control.
Cardiovascular disease (CVD) risk reduction.
Knee osteoarthritis (OA), with pain relief data from trials.

Trials also explore obstructive sleep apnea (OSA) and weight maintenance (ClinicalTrials.gov).[3]

Current Development Status: Phase 3 TRIUMPH Program as of 2026

As of early 2026, retatrutide is in Phase 3 under the TRIUMPH program. Seven trials started in 2024 test various doses and groups.

No FDA approval yet—it's investigational. Full data expected late 2026 supports the retatrutide nda submission timeline q4 2026 q1 2027 fda review.

Retatrutide Phase 3 Clinical Trial Status: TRIUMPH Program Timeline

The TRIUMPH program includes seven trials evaluating retatrutide's safety and efficacy. Most primary completions are set for mid-2026, paving the way for NDA filing.

Phase 2 benchmarks guide expectations, with superior results to existing drugs.

Key TRIUMPH Trials and Completion Dates (TRIUMPH-1, TRIUMPH-2, TRIUMPH-3, TRIUMPH-4)

Here's a snapshot of key trials:

Trial	Focus	Est. Primary Completion
TRIUMPH-1	Obesity/overweight	May 2026
TRIUMPH-2	Obesity + T2D	Jan-May 2026
TRIUMPH-3	Obesity + CVD	May 2026
TRIUMPH-4	Obesity + Knee OA	Completed (Dec 2025)

TRIUMPH-4 met goals early—see Detailed TRIUMPH-4 knee osteoarthritis results for full breakdown (Eli Lilly).[1] These align with the retatrutide nda submission timeline q4 2026 q1 2027 fda review.

Other trials like TRIUMPH-8 (weight maintenance) run to 2027 but provide supporting data.

Phase 2 Efficacy Benchmarks: 24.2%-28.7% Weight Loss

Phase 2 showed dose-dependent weight loss:

8 mg: Up to 24.2% over 48 weeks.
12 mg: Up to 28.7% mean reduction.

This beats semaglutide's ~15-20% in head-to-head comparisons. Data supports obesity and T2D labels.

Ongoing Trials for OSA, Weight Maintenance, and Comorbidities

Additional studies cover:

OSA in obese patients.
Long-term weight maintenance post-loss.
Comorbidities like fatty liver.

These bolster the NDA package in the retatrutide nda submission timeline q4 2026 q1 2027 fda review (ClinicalTrials.gov).[3]

Expected Retatrutide NDA Submission Timeline: Q4 2026 or Q1 2027

Eli Lilly aims for NDA filing after Phase 3 data readout. Q4 2026 is optimistic; Q1 2027 more likely with analysis time.

Pre-submission FDA meetings will confirm the package.

Triggers for NDA Filing: Complete Phase 3 Data and FDA Pre-Submission Meetings

NDA requires:

Full clinical data from TRIUMPH trials.
Preclinical, manufacturing, and chemistry info.
Positive end-of-Phase 2/3 FDA talks.

Trials wrap late 2026, enabling filing soon after.

Optimistic Q4 2026 Scenario vs. Likely Q1 2027 Delay Factors

Q4 2026: All trials positive, quick analysis—file Oct-Dec.
Q1 2027: Extra safety review or data integration needed.

Delays are low-risk per precedents.

Comparison to Tirzepatide: Lessons from Eli Lilly's Past Approvals

Tirzepatide: Phase 3 end 2021 → T2D approval May 2022, obesity Nov 2023. Retatrutide follows suit, fitting retatrutide nda submission timeline q4 2026 q1 2027 fda review (FDA).[5]

FDA Review Process After Retatrutide NDA Submission

Post-submission, FDA has 60 days to accept the NDA. Then, a PDUFA date sets the review clock.

Standard path: 10-12 months; priority shortens it.

Filing Acceptance: 60-Day Review and PDUFA Date Assignment (e.g., October 2027)

Q4 2026 filing → Acceptance ~Jan 2027 → PDUFA Oct 2027. Routine for Lilly.

Standard 10-12 Month Review vs. Priority Review (6-8 Months)

Standard: Full data scrutiny.
Priority: For unmet needs like obesity—see Retatrutide priority review for GLP-1 obesity drugs.

Breakthrough status possible from Phase 2 data.

Potential Breakthrough Therapy Designation and Expedited Pathways

Phase 2 weight loss qualifies for fast-track. This fits retatrutide nda submission timeline q4 2026 q1 2027 fda review acceleration (FDA Breakthrough).[4]

Retatrutide Efficacy Results Supporting NDA Approval

Phase 3 data builds on Phase 2, with TRIUMPH-4 topping charts. Superiority claims drive approval odds.

Phase 3 Highlights: 28.7% Weight Loss in TRIUMPH-4 (Knee OA)

TRIUMPH-4: 28.7% loss at 12 mg over 68 weeks; 75.8% knee pain drop. Backbone for obesity NDA—details in TRIUMPH-1 80-week weight loss data.

Superiority Over Semaglutide and Implications for Obesity/T2D

Beats semaglutide (Wegovy ~15%):

Greater fat loss.
Better A1C for T2D.
CVD benefits emerging.

Supports labels in retatrutide nda submission timeline q4 2026 q1 2027 fda review.

Supporting Data from CVD and Maintenance Trials

TRIUMPH-3 shows CV markers improve. Maintenance trials ensure lasting effects (Eli Lilly).[1]

Safety Data and Side Effects: Key NDA Review Considerations

Safety mirrors GLP-1 class but with unique signals. Phase 3 data key for FDA.

No red flags halting progress.

Known Issues: Dysesthesia from Phase 2 and GI Effects

Common:

GI: Nausea, vomiting (mild-moderate).
Dysesthesia: Skin tingling (Phase 2)—see Managing retatrutide dysesthesia in Phase 3.

Dose titration helps.

Phase 3 Safety Profile: Discontinuations and Monitoring Needs

Low discontinuations expected. Long-term CV safety monitored.

Impact on FDA Review and Potential Post-Approval Requirements

Clean profile aids approval. Possible REMS for GI risks in retatrutide nda submission timeline q4 2026 q1 2027 fda review.

Risks and Delays for Retatrutide NDA Submission and FDA Review

Base case: On track. Risks low but monitored.

Safety Signals, Manufacturing, or Data Analysis Delays

Minor slips from data crunching.

Complete Response Letter Scenarios and Advisory Committee Risks

Rare CRL—see Risks of FDA complete response letters post-NDA. No adcom likely.

Low-Probability Slips Beyond Q1 2027

Only major issues push further.

Projected FDA Approval, PDUFA Date, and Commercial Launch

Approval mid-to-late 2027 realistic.

Best-Case: Mid-2027 Approval with Priority Review

Q4 2026 NDA + priority → Q2 2027.

Realistic Timeline: Late 2027 PDUFA and Early 2028 Launch

Standard: PDUFA Oct 2027—see Retatrutide PDUFA date projections for 2027. Launch Q1 2028.

Post-Approval: Manufacturing Ramp-Up and Availability

2-4 months to scale; shortages possible initially.

Conclusion: What to Watch in the Retatrutide NDA Timeline

Summary of Q4 2026-Q1 2027 Milestones

Key dates in retatrutide nda submission timeline q4 2026 q1 2027 fda review:

Phase 3 wrap: Late 2026.
NDA: Q4 2026/Q1 2027.
PDUFA: Late 2027.
Approval: 2027-2028.
Launch: Early 2028.

Investor and Patient Implications

Investors eye stock boosts on data. Patients gain potent option soon. Watch Lilly updates (Investor Site).[1]

Note: These projections are forward-looking statements based on publicly available data as of April 2026. Actual timelines may change due to trial outcomes, FDA feedback, manufacturing, or other factors.